Axcella Health appoint new CEO

Bill Hinshaw, former Executive Vice President of US Oncology at Novartis, is to replace Bob Connelly to become CEO at Axcella Health. Bill said: “I was drawn to Axcella by the importance and fundamental nature of their science, and the potential of their platform to transform patients’ lives. I am thrilled to join the company at this critical stage and look forward to leading the organization with passion and purpose into its next phase of growth”. This is a big change for Bill who was responsible for over $6 billion in revenue through Novartis’ US oncology unit.
David Epstein, Chairman of the Axcella Board of Directors and Executive Partner of Flagship Pioneering said: “Bill joins Axcella’s leadership team at a key inflection point in the company’s strategic and clinical evolution with a proven track record of overseeing the successful clinical development and commercialization of numerous therapeutic franchises across multiple geographies. Axcella has made substantial progress in 2018 as we continue advancing our proprietary platform and expanding our pipeline of novel metabolic modulators. We are excited to have Bill on board to lead the company through its next phase. I want to thank Bob Connelly whose leadership and dedication over the last five years have put Axcella on our current growth trajectory.”